Prospective, observational, multicenter study regarding the safety of Gammanorm in autoimmune diseases

Trial Profile

Prospective, observational, multicenter study regarding the safety of Gammanorm in autoimmune diseases

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 15 Sep 2016

At a glance

  • Drugs Immune globulin (Primary)
  • Indications Dermatomyositis; Inclusion body myositis; Multifocal motor neuropathy; Polymyositis; Polyneuropathy
  • Focus Adverse reactions
  • Acronyms Immunorm Study
  • Sponsors Octapharma
  • Most Recent Events

    • 02 Sep 2016 Status changed from not yet recruiting to recruiting.
    • 21 Jul 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top